Quarterly report · Q2

Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥112.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥55.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥208.2bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥97.6bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥51.2bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥36.3bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥17.6bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥61.9bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥37.3bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥38.1bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥18.3bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥96.2bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥62.2bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥24.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥63.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥40.8bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥25.0bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥26.0bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥12.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥42.7bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥25.8bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥377.7bnat 2022-09-30Cons.Assets IFRS
Total assets¥346.0bnat 2022-03-31Cons.Assets IFRS
Total assets¥308.4bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥86.4bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥82.0bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥291.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥237.7bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥207.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥284.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥257.8bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥231.4bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥100.2bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥87.0bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥89.1bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥25.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥52.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥18.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥18.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥23.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥14.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥16.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥13.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥35.442022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.582022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥94.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥60.092021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥36.862021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥35.422022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.572022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥93.982021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥60.042021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥36.832021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio75.3%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.5%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.0%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥701m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥231m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥8.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥445m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥179m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.5bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥634m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥14.0bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥6.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.7bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥347m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥185m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-09-30¥42.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-07-01 → 2022-09-30¥22.3bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-09-30¥40.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-07-01 → 2022-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥664m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-07-01 → 2022-09-30¥10.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥2m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥18.5bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥304m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥865m
—segment totalrevenue2022-04-01 → 2022-09-30¥113.9bn
—segment totalrevenue2022-07-01 → 2022-09-30¥55.9bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥111.2bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥54.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.7bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥1.0bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥36.9bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥17.6bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥2.5bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥1.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥2.5bn
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥1.5bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥520m
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥376m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2021-04-01 → 2021-09-30¥8.2bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2021-07-01 → 2021-09-30¥3.3bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2021-04-01 → 2021-09-30¥7.8bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2021-07-01 → 2021-09-30¥3.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥364m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥338m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2021-04-01 → 2021-09-30¥3.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2021-07-01 → 2021-09-30¥979m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2021-04-01 → 2021-09-30¥10.1bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2021-07-01 → 2021-09-30¥5.3bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2021-04-01 → 2021-09-30¥9.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2021-07-01 → 2021-09-30¥5.0bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥483m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥288m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.1bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2021-07-01 → 2021-09-30¥1.2bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2021-04-01 → 2021-09-30¥38.4bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2021-07-01 → 2021-09-30¥19.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2021-04-01 → 2021-09-30¥37.1bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2021-07-01 → 2021-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥622m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2021-04-01 → 2021-09-30¥16.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2021-07-01 → 2021-09-30¥8.5bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2021-04-01 → 2021-09-30¥24.4bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2021-07-01 → 2021-09-30¥11.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2021-04-01 → 2021-09-30¥24.4bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2021-07-01 → 2021-09-30¥11.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥12m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥1m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2021-04-01 → 2021-09-30¥38.1bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2021-07-01 → 2021-09-30¥25.2bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2021-04-01 → 2021-09-30¥17.5bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2021-07-01 → 2021-09-30¥12.2bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2021-04-01 → 2021-09-30¥17.2bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2021-07-01 → 2021-09-30¥11.9bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥238m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥238m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2021-07-01 → 2021-09-30¥2.0bn
—segment totalrevenue2021-04-01 → 2021-09-30¥98.6bn
—segment totalrevenue2021-07-01 → 2021-09-30¥52.0bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥96.2bn
—segment totalrevenue external2021-07-01 → 2021-09-30¥50.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥2.4bn
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥1.5bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥62.9bn
—segment totalsegment profit2021-07-01 → 2021-09-30¥37.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 824
ItemContextValueUnit
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember19447000000JPY
Equity IFRSCurrentQuarterInstant_RetainedEarningsIFRSMember206160000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember284479000000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember6827000000JPY
Equity IFRSCurrentQuarterInstant291306000000JPY
Profit loss before tax IFRSPrior1YTDDuration62232000000JPY
Profit loss before tax IFRSCurrentYTDDuration38067000000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration2977000000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration3490000000JPY
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration-JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration-820000000JPY
Gain relating to loss of control over subsidiaries ope cf IFRSPrior1YTDDuration-9443000000JPY
Gain relating to loss of control over subsidiaries ope cf IFRSCurrentYTDDuration-JPY
Loss gain on change in equity ope cf IFRSPrior1YTDDuration-21906000000JPY
Loss gain on change in equity ope cf IFRSCurrentYTDDuration-JPY
Finance income ope cf IFRSPrior1YTDDuration-320000000JPY
Finance income ope cf IFRSCurrentYTDDuration-1806000000JPY
Finance costs ope cf IFRSPrior1YTDDuration29000000JPY
Finance costs ope cf IFRSCurrentYTDDuration32000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration462000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration-614000000JPY
Loss gain on sale of financial assets measured at fair value through profit or loss ope cf IFRSPrior1YTDDuration-43000000JPY
Loss gain on sale of financial assets measured at fair value through profit or loss ope cf IFRSCurrentYTDDuration-JPY
Loss gain on valuation of financial assets measured at fair value through profit or loss ope cf IFRSPrior1YTDDuration-115000000JPY
Loss gain on valuation of financial assets measured at fair value through profit or loss ope cf IFRSCurrentYTDDuration-253000000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration-3960000000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration3754000000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration3391000000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration-1668000000JPY
Increase decrease in provisons for customer loyalty program ope cf IFRSPrior1YTDDuration345000000JPY
Increase decrease in provisons for customer loyalty program ope cf IFRSCurrentYTDDuration236000000JPY
Decrease increase in other current assets ope cf IFRSPrior1YTDDuration-431000000JPY
Decrease increase in other current assets ope cf IFRSCurrentYTDDuration-1298000000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration-2810000000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-2071000000JPY
Subtotal ope cf IFRSPrior1YTDDuration30408000000JPY
Subtotal ope cf IFRSCurrentYTDDuration37049000000JPY
Interest and dividends received ope cf IFRSPrior1YTDDuration1087000000JPY
Interest and dividends received ope cf IFRSCurrentYTDDuration667000000JPY
Interest paid ope cf IFRSPrior1YTDDuration-29000000JPY
Interest paid ope cf IFRSCurrentYTDDuration-32000000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-12872000000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-12469000000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration18595000000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration25215000000JPY
Payments into time deposits inv cf IFRSPrior1YTDDuration-18830000000JPY
Payments into time deposits inv cf IFRSCurrentYTDDuration-9407000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSPrior1YTDDuration15186000000JPY
Proceeds from withdrawal of time deposits inv cf IFRSCurrentYTDDuration5328000000JPY
Purchase of financial assets measured at fair value inv cf IFRSPrior1YTDDuration-323000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass